Jiang Jinyan, Li Xinyang, Mori Takahiro, Awakawa Takayoshi, Abe Ikuro
Graduate School of Pharmaceutical Sciences, The University of Tokyo.
Collaborative Research Institute for Innovative Microbiology, The University of Tokyo.
Chem Pharm Bull (Tokyo). 2021;69(5):444-446. doi: 10.1248/cpb.c21-00123.
Structurally diverse fungal meroterpenoids are promising drug seed compounds. To obtain unnatural, novel meroterpene scaffolds, we tested combinatorial biosynthesis by co-expressing functionally distinct terpene cyclase (TPC) genes, pyr4, ascF, andB, or cdmG, with the biosynthetic genes for the production of a TPC substrate, (10'R)-epoxyfarnesyl-dimethylorsellinic acid-3,5-methyl ester, in Aspergillus oryzae NSAR1 as a heterologous host. As a result, all of the tested TPCs afforded the same two novel mono-cyclization products. This study provides important information on the substrate scope of the TPCs, and will contribute to the production of unnatural, novel molecules for future drug discovery.
结构多样的真菌聚酮萜类化合物是很有前景的药物种子化合物。为了获得非天然的新型聚酮萜类骨架,我们通过在米曲霉NSAR1作为异源宿主中共同表达功能不同的萜烯环化酶(TPC)基因pyr4、ascF和B或cdmG与用于生产TPC底物(10'R)-环氧法呢基-二甲基苔色酸-3,5-甲酯的生物合成基因,测试了组合生物合成。结果,所有测试的TPC都产生了相同的两种新型单环化产物。本研究提供了关于TPC底物范围的重要信息,并将有助于生产非天然的新型分子用于未来的药物发现。